FNMAT Stock | News | Quote | Stock Forum | Wednesday, October

New Post Public Reply Private Reply Replies (0) Message Board
Rosner
Fannie Mae FNMAT Company Overview 

Fannie Mae FNMAT Current Price and Quotes
Last Price 8.81
Previous Close 8.50 Open 8.55
Daily Range 8.81 - 8.50 52wk Range 9.21 - 1.60
Volume 53,711 Dividend N/A
Average Vol (3m) 99,529 Yield N/A

FNMAT Stock Message Board http://investorshangout.com/search?q=FNMAT&am...mp;yt1=Go!

Last Updated: Wednesday, October 30, 2013 01:48:27 AM

Fannie Mae FNMAT
Company Information

3900 Wisconsin Avenue, N.W.
Washington, DC 20016

Website: http://www.fanniemae.com
Phone: 202-752-7000
Email: info@fanniemae.com

Fannie Mae FNMAT
Fannie Mae is a government-sponsored enterprise that was chartered by Congress in 1938 to support liquidity, stability and affordability in the secondary mortgage market, where existing mortgage-related assets are purchased and sold.

Fannie Mae FNMAT
Financial Reportings and Disclosures

Reporting Status U.S. Reporting: SEC Filer
Audited Financials Audited
Latest Report Jun 30, 2013 10-Q
CIK 0000310522
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data

SIC - Industry Classification 6111 - Federal and federally sponsored credit
Incorporated In: USA
Year of Inc. Not Available
Employees 6000 a/o Dec 31, 2009
Company Officers/Contacts

Timothy J. Mayopoulous CEO, President
Susan R. McFarland EVP, CFO
Company Directors

Phillip Laskawy Chairman
Robert H. Herz
Company Notes

Formerly=Federal National Mortgage Association until 12-96
Service Providers

Auditor/Accountant
Deloitte & Touche LLP
225 W. Santa Clara St.
San Jose, CA, 95113
United States

Legal Counsel
Not Available
Investor Relations Firm
Not Available

Fannie Mae FNMAT
FNMAT Security Details Other Company Securities

Share Structure

Market Value1 $704,800,000 a/o Oct 29, 2013
Shares Outstanding 80,000,000 a/o Jun 18, 2008
Float Not Available
Authorized Shares Not Available
Par Value  No Par Value
Shareholders

Shareholders of Record Not Available
Corporate Actions

Ex. Date Record Date Pay Date
Dividend () Jun 12, 2008 Jun 16, 2008 Jun 30, 2008
Short Selling Data

Short Interest 2,022,282 (-0.02%)
Sep 30, 2013
Significant Failures to Deliver  No
Transfer Agent(s)



Fannie Mae FNMAT Financials

Fannie Mae FNMAT Recent News

Oct 23, 2013 New Equity Reports on Fannie Mae (OTC: FNMA) and Freddie Mac (OTC: FMCC)
Oct 22, 2013 Dr. Amy E. Alving Elected to Fannie Mae Board of Directors
Oct 17, 2013 Fannie Mae Prices $1.03 Billion Multifamily DUS REMIC (FNA 2013-M13) Under Its Fannie Mae GeMS(TM) Program
Oct 17, 2013 Fiscal Debate Weighs on Fragile Economic Recovery
Oct 7, 2013 Consumers in Cautionary Holding Pattern as Fiscal Policy Debate Unfolds
Sep 30, 2013 Fannie Mae Releases August 2013 Monthly Summary
Sep 24, 2013 FNMA, AAMRQ, FMCC and NNRX added to OTC Gainers Watch List at EPR
Sep 20, 2013 Fannie Mae Prices $1.09 Billion Multifamily DUS REMIC (FNA 2013-M12) Under Its Fannie Mae GeMS Program
Sep 17, 2013 Uneven Economic Growth Clouds Picture of Modest Recovery Trend
Sep 12, 2013 FNMA, WTER, ADXS and FMCC added to OTC Active Stock Watch List at EPR

1
2
next >

FNMAT Fannie Mae Research DD Guide

Stock Message Board http://investorshangout.com/search?q=FNMAT&am...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/FNMAT/quote
Stock Chart http://www.otcmarkets.com/stock/FNMAT/chart
Company Info http://www.otcmarkets.com/stock/FNMAT/company-info
Recent News http://www.otcmarkets.com/stock/FNMAT/news
Financials http://www.otcmarkets.com/stock/FNMAT/financials
Filings and Disclosure http://www.otcmarkets.com/stock/FNMAT/filings
Short Sales http://www.otcmarkets.com/stock/FNMAT/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/FNMAT/insider-transactions
Research Reports http://www.otcmarkets.com/stock/FNMAT/research
Summary http://finance.yahoo.com/q?s=FNMAT
Historical Prices http://finance.yahoo.com/q/hp?s=FNMAT+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=FNMAT
Basic Chart http://finance.yahoo.com/q/bc?s=FNMAT+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=FNMAT+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=FNMAT+Headlines
Press Releases http://finance.yahoo.com/q/p?s=FNMAT+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=FNMAT+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=FNMAT+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=FNMAT+Industry
Major Holders http://finance.yahoo.com/q/mh?s=FNMAT+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=FNMAT+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=FNMAT+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=FNMAT
Balance Sheet http://finance.yahoo.com/q/bs?s=FNMAT
Cash Flow http://finance.yahoo.com/q/cf?s=FNMAT+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/FNMAT
Market Watch http://www.marketwatch.com/investing/stock/FNMAT
Bloomberg http://www.bloomberg.com/quote/FNMAT:US
Morningstar http://quotes.morningstar.com/stock/s?t=FNMAT
Bussinessweek http://investing.businessweek.com/research/st...cker=FNMAT
Barchart http://www.barchart.com/quotes/stocks/FNMAT
OTC Short Report http://otcshortreport.com/index.php?index=FNMAT
Investopedia http://www.investopedia.com/markets/stocks/FNMAT/?wa=0

List of all stock message boards and tickers for OTC BB Pinks & Penny Stocks http://investorshangout.com/board?categoryid=OTC
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Terminus Ballet: A Decade of Defying Dance Norms

Updated Category News Views 135

A Dance Company's Journey of Transformation An anniversary represents more than just a celebration; it's a reminder of the road traveled. On Jan. 30, 2027, Terminus Modern Ballet Theatre will mark its 10th anniversary, encapsulating a decade of defiance against the staid conventions binding classical ballet. This isn't just about pirouettes and pliés—it's dance with a...

Continue Reading
Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 35

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
Lennar Faces Securities Fraud Lawsuit: Investor Insights

Updated Category News Views 20

Investors in Lennar: Navigating the Legal Storm Hold onto your hats, folks. Lennar Corporation (NYSE: LEN) is up against it with a brand-spanking-new securities fraud lawsuit helmed by Schall, Brown & Schwartz LLP (SBS). This isn't just a couple of investors grumbling over cocktails; it’s a full-blown class action that’s waving the legal banner under the Securities...

Continue Reading
Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 78

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
Tenax Therapeutics Facing Class Action: DEC 28 Deadline

Updated Category News Views 70

Legal Storm Over Tenax Therapeutics Just what the doctor didn't order—legal headaches for Tenax Therapeutics, Inc. (NASDAQ:TENX). Yup, folks, buckle up because we're diving into another class action mudslinging match that’s setting the markets wagging. Berger Montague's law trebuchet is aimed squarely at Tenax and every investor should know the target’s outline....

Continue Reading
Graphic Packaging Shakes Up Leadership and Supply Chain

Updated Category News Views 29

New Leadership Takes the Helm at Graphic Packaging What do you do when you want to streamline an operation that spans continents? Well, if you're Graphic Packaging Holding Company (NYSE: GPK), you bring in fresh leadership to serenade the chaos into a well-oiled machine. Starting December 1, 2026, D. Keith Hamilton will be sinking his teeth into North America Mills &...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 194

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 119

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 117

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading
Saint Luis Rey Launches Exclusive Palatinos Vitola

Updated Category News Views 59

New Beginnings for the Saint Luis Rey Brand You think you've seen it all in the cigar world, but then comes a debut like this that lights a fire under the lush tradition of Cuba. Enter Saint Luis Rey's new Palatinos vitola, a blend wrapped in the mystique of exclusivity for La Casa del Habano and Habanos Specialists. Whether you're a seasoned connoisseur or just dipping...

Continue Reading

Top 5 Most Recently Viewed Articles

Ocuphire Pharma Faces Scrutiny Over Shareholder Obligations

Updated Category News Views 81

Ocuphire Pharma Under Investigation by Ademi LLP Recently, there have been growing concerns regarding the fiduciary responsibilities of Ocuphire Pharma, Inc. (NASDAQ: OCUP) to its public shareholders. Ademi LLP has initiated an investigation focused on whether the company is adequately protecting the interests of its shareholders amidst its dealings with Opus Genetics....

Continue Reading
Investigation Into Shareholder Claims Against AMLX, FIVE, HUM, and VSTS

Updated Category News Views 190

Grabar Law Office Investigates Shareholders' Rights Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), Five Below, Inc. (NASDAQ: FIVE), Humana Inc. (NYSE: HUM), and Vestis Corp. (NYSE: VSTS) shareholders may have claims worth exploring. Grabar Law Office wants to inform these shareholders about the ongoing investigations into potential securities fraud that could have affected...

Continue Reading
Investors Seek Recovery in Class Action Against Paragon 28, Inc.

Updated Category News Views 109

Class Action Lawsuit Filed for Paragon 28, Inc. Investors We are reaching out to inform investors about an important class action securities lawsuit involving Paragon 28, Inc. This initiative aims to recover losses for investors who may have been adversely affected by purported securities fraud associated with the company. Details of the Class Action The class action...

Continue Reading
Alto Ingredients, Inc. Announcement for Q2 2025 Results

Updated Category News Views 165

Alto Ingredients, Inc. to Announce Second Quarter Financial Results Alto Ingredients, Inc. (NASDAQ: ALTO), a prominent producer and distributor of specialty alcohols and renewable fuels, is set to release its financial results for the second quarter of 2025. This announcement will take place after the market closes on Wednesday, August 6, 2025. Conference Call Details...

Continue Reading
Phare Bio Secures $27 Million to Revolutionize Antibiotic Discovery

Updated Category News Views 226

Phare Bio scored big back in 2024 with up to $27 million in funding from the Advanced Research Projects Agency for Health (ARPA-H). This isn’t just pocket change; it’s a lifeline aimed at supercharging their generative artificial intelligence (AI) platform. Teaming up with MIT's Collins Lab and Harvard's Wyss Institute, they set their sights on developing new classes...

Continue Reading